All these results, together with the expression of COX-2 in KS lesions, contribute to defining COX-2 as a potential target by low-toxicity NSAIDs for the prevention and treatment of KSHV-oncogenesis in HIV infected populations. This evidence concerns the gene PTGS2 and Kaposi's sarcoma.